SCHEMBL5541960

SCHEMBL5541960

N=C(N)c1cccc(C(=O)NCCCCCNC(=O)c2cccc(C(=N)N)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.61
F10 P00742 7/20 0.59
ITGB3 P05106 5/20 0.54
ITGA2B P08514 5/20 0.54
LMNA P02545 1/20 0.54
PRSS1 P07477 2/20 0.53
PLG P00747 1/20 0.52
PROC P04070 1/20 0.52
NAAA Q02083 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14132308 0.84 F10 (0.81) F10PRSS1PLGPROC
SCHEMBL9322112 0.83 SMN1; SMN2 (0.65) SMN1; SMN2LMNANAAAHDAC3HDAC4
SCHEMBL20999952 0.83 SMN1; SMN2 (0.65) SMN1; SMN2LMNANAAAHDAC3HDAC4
SCHEMBL284798 0.83 SMN1; SMN2 (0.65) SMN1; SMN2LMNANAAAHDAC3HDAC4
SCHEMBL9321159 0.83 SMN1; SMN2 (0.65) SMN1; SMN2LMNANAAAHDAC3HDAC4
SCHEMBL14599582 0.83 MAPK1 (0.61) F10ITGB3ITGA2BPRSS1NAAA
SCHEMBL14599527 0.83 MAPK1 (0.61) F10ITGB3ITGA2BPRSS1NAAA
SCHEMBL14599618 0.83 MAPK1 (0.61) F10ITGB3ITGA2BPRSS1NAAA
SCHEMBL14599581 0.83 MAPK1 (0.61) F10ITGB3ITGA2BPRSS1NAAA
SCHEMBL9491823 0.81 SMN1; SMN2 (0.67) SMN1; SMN2LMNANAAAHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262223-B2 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-28 US claimed
EP-1715857-A1 AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS Neurochem (International) Limited (CH) 2006-11-02 EP claimed
WO-2005079780-A1 AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-09-01 WO claimed
US-20050182118-A1 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-08-18 US claimed
US-7262223-B2 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-28 US disclosed
US-7262223-B2 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182118-A1 Amidine derivatives for treating amyloidosis APP, IAPP, GRN SMN1; SMN2 19/4885F10 2178/4885ITGB3 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.